Detalhe da pesquisa
1.
Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors.
Cancer
; 129(12): 1904-1918, 2023 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37042037
2.
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy.
Blood
; 140(3): 285-289, 2022 07 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35507690
3.
Real-world study of the use of azacitidine in myelodysplasia in Australia.
EJHaem
; 5(3): 527-534, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38895081
4.
Epigenetic Priming by Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-cell Lymphoma.
Cancer Res Commun
; 4(6): 1441-1453, 2024 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38727208
5.
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.
Blood Adv
; 8(8): 2020-2029, 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38231126
6.
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Lancet Haematol
; 11(1): e15-e26, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38135371
7.
Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Invest New Drugs
; 31(2): 417-24, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22918720
8.
A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
Invest New Drugs
; 31(3): 742-50, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23054208
9.
Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients.
Leukemia
; 37(11): 2187-2196, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37591941
10.
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.
Blood Adv
; 7(17): 5027-5037, 2023 09 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37276510
11.
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
PLoS One
; 17(10): e0276211, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36215283
12.
Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878).
Clin Lung Cancer
; 22(6): 541-548, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34140248
13.
Antagonism of inhibitors of apoptosis proteins reveals a novel, immune response-based therapeutic approach for T-cell lymphoma.
Blood Adv
; 5(20): 4003-4016, 2021 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34474469
14.
Methylomic Signatures of High Grade Serous Ovarian Cancer.
Epigenetics
; 16(11): 1201-1216, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33289590
15.
A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer.
Cancer Med
; 10(1): 156-163, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33135391
16.
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
PLoS One
; 16(12): e0261994, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34941969
17.
Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
Invest New Drugs
; 33(6): 1292, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26407571
18.
Oral Azacitidine and Cedazuridine Approximate Parenteral Azacitidine Efficacy in Murine Model.
Target Oncol
; 15(2): 231-240, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32222953
19.
Correction: A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent.
PLoS One
; 15(11): e0242974, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33216806
20.
A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma.
Clin Cancer Res
; 26(12): 2819-2826, 2020 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31900279